Department of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan , Ann Arbor, Michigan 48109, United States.
NanoBio Corporation , 2311 Green Road, Ann Arbor, Michigan 48105, United States.
Mol Pharm. 2017 Sep 5;14(9):3228-3237. doi: 10.1021/acs.molpharmaceut.7b00586. Epub 2017 Aug 22.
Herein we describe a formulation of self-encapsulating poly(lactic-co-glycolic acid) (PLGA) microspheres for vaccine delivery. Self-healing encapsulation is a novel encapsulation method developed by our group that enables the aqueous loading of large molecules into premade PLGA microspheres. Calcium phosphate (CaHPO) adjuvant gel was incorporated into the microspheres as a protein-trapping agent for improved encapsulation of antigen. Microspheres were found to have a median size of 7.05 ± 0.31 μm, with a w/w loading of 0.60 ± 0.05% of ovalbumin (OVA) model antigen. The formulation demonstrated continuous release of OVA over a 49-day period. Released OVA maintained its antigenicity over the measured period of >21 days of release. C57BL/6 mice were immunized via the intranasal route with prime and booster doses of OVA (10 μg) loaded into microspheres or coadministered with cholera toxin B (CTB), the gold standard of mucosal adjuvants. Microspheres generated a Th2-type response in both serum and local mucosa, with IgG antibody responses approaching those generated by CTB. The results suggest that this formulation of self-encapsulating microspheres shows promise for further study as a vaccine delivery system.
本文描述了一种用于疫苗传递的自包封聚(乳酸-共-乙醇酸)(PLGA)微球制剂。自修复包封是我们小组开发的一种新的包封方法,使大分子能够在预先制备的 PLGA 微球中进行水载。磷酸钙(CaHPO)佐剂凝胶被掺入微球中,作为一种蛋白质捕获剂,以提高抗原的包封效率。研究发现,微球的平均粒径为 7.05±0.31μm,卵清蛋白(OVA)模型抗原的载药量为 0.60±0.05%(w/w)。该制剂表现出OVA 的持续释放,持续时间超过 49 天。在释放的 >21 天内,释放的 OVA 保持其抗原性。C57BL/6 小鼠通过鼻内途径用微球负载的 OVA(10μg)进行初免和加强免疫,或与霍乱毒素 B(CTB)共同给药,CTB 是粘膜佐剂的金标准。微球在血清和局部粘膜中均产生 Th2 型反应,IgG 抗体反应接近 CTB 产生的反应。结果表明,这种自包封微球的制剂有望作为疫苗传递系统进一步研究。